| 0 (0%) | 10-15 12:14 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 41.1 |
1-year : | 48 |
| Resists | First : | 35.18 |
Second : | 41.1 |
| Pivot price | 34.49  |
|||
| Supports | First : | 34.02 |
Second : | 33.29 |
| MAs | MA(5) : | 33.97 |
MA(20) : | 34.54 |
| MA(100) : | 33.42 |
MA(250) : | 33.01 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 42.4 |
D(3) : | 26.7 |
| RSI | RSI(14): 48.3 |
|||
| 52-week | High : | 35.29 | Low : | 27.78 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ SPDV ] has closed above bottom band by 38.5%. Bollinger Bands are 27.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 34.27 - 34.43 | 34.43 - 34.58 |
| Low: | 33.21 - 33.4 | 33.4 - 33.58 |
| Close: | 33.86 - 34.18 | 34.18 - 34.47 |
Wed, 15 Oct 2025
Can SPDV stock reach $200 price target - Market Trend Review & Weekly Momentum Stock Picks - newser.com
Tue, 14 Oct 2025
Will SPDV stock benefit from mergers - July 2025 EndofMonth & Weekly Top Gainers Alerts - newser.com
Sun, 10 Aug 2025
(PDF) A Case Report of Multibacillary Leprosy Presenting with Multiple Outbreaks of Erythema Nodosum Leprosum - researchgate.net
Thu, 31 Jul 2025
Complementary roles of structure and variant effect predictors in RyR1 clinical interpretation - medRxiv
Sat, 10 May 2025
SPY: Buy In May For V-Recovery, Even If You Go Away (NYSEARCA:SPY) - Seeking Alpha
Thu, 03 Apr 2025
Structure-informed classification of RyR1 variants highlights limitations of current predictors and enables clinical interpretation - medRxiv
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|